文献速递皮肤肿瘤

荷兰默克尔细胞癌1993年以来的治疗与生存:基于人群的队列研究

Treatment and survival of Merkel cell carcinoma since 1993: A population-based cohort study in The Netherlands.
PubMed 文献 · J Am Acad Dermatol · 2019-01-29

该研究基于荷兰癌症登记处1993至2016年1977例默克尔细胞癌患者,描述其发病率、治疗与生存。发病率从1993年0.17/10万人年升至2016年0.59/10万人年,5年相对生存率低(63.0%)且未改善。男性、高龄、淋巴结及远处转移与更高死亡风险相关。

要点

  • 荷兰MCC发病率从1993年0.17/10万人年升至2016年0.59/10万人年。
  • 5年相对生存率为63.0%且未见改善。
  • 男性、高龄、淋巴结及远处转移与更高死亡风险相关。

核心结论

  • 荷兰MCC发病率持续上升,诊断后生存率仍低,强调需实施新疗法。

研究设计与样本

  • 基于荷兰癌症登记处的基于人群的队列研究,纳入1993至2016年诊断的1977例MCC患者。

主要发现

  • 发病率从1993年0.17/10万人年升至2016年0.59/10万人年。
  • 诊断时平均年龄75.5岁,59.8%的MCC仅接受手术治疗。
  • 5年相对生存率为63.0%且未改善。
  • 男性死亡风险更高(HR 1.24;95%CI 1.11-1.39)。
  • 高龄(HR 1.07;95%CI 1.06-1.07)、淋巴结转移(HR 1.26;95%CI 1.08-1.48)及远处转移(HR 2.44;95%CI 1.99-2.99)与更高死亡风险相关。

临床怎么用

  • 临床应关注MCC发病率上升趋势,对男性、高龄及有淋巴结或远处转移者加强风险管理。

局限性

  • 缺乏死因、合并症及病理切缘数据,可能导致数据解读偏差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Merkel cell carcinoma (MCC) is a rare and potentially lethal skin cancer. MCC is known for its potential rapid growth and its propensity to metastasize. OBJECTIVE: To describe the incidence, treatment, and survival of MCC in a population-based setting. METHODS: All MCCs diagnosed in The Netherlands between 1993 and 2016 were selected from the Netherlands Cancer Registry. Patient and tumor characteristics, therapy, and vital status were obtained. Cox proportional hazards were computed, and relative survival analyses were performed. RESULTS: Our cohort included 1977 patients with MCC. Incidence increased from 0.17 per 100,000 person-years in 1993 to 0.59 per 100,000 in 2016. The mean age at diagnosis was 75.5. Most MCCs (59.8%) were treated with surgery alone. Relative 5-year survival was low (63.0%) and did not improve. Mortality was higher among males (hazard ratio [HR], 1.24; 95% confidence interval [CI], 1.11-1.39), higher age (HR, 1.07; 95% CI, 1.06-1.07), and nodal (HR, 1.26; 95% CI, 1.08-1.48) and distant spread of disease (HR, 2.44; 95% CI, 1.99-2.99). LIMITATIONS: We lacked data on cause of death, comorbidity, and pathologic margins, which may have led to misinterpretation of the data. CONCLUSION: This study shows continuously increasing incidence rates of MCC in The Netherlands. Survival after a diagnosis of MCC remained low. Our results emphasize the need for implementation of new therapies.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Uitentuis SE, Louwman MWJ, van Akkooi ACJ, et al. Treatment and survival of Merkel cell carcinoma since 1993: A population-based cohort study in The Netherlands. J Am Acad Dermatol. 2019. PMID: 30703452. doi:10.1016/j.jaad.2019.01.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。